0
Chiasma, Inc. Banner Image

Chiasma, Inc. has reached its limit for free report views

Work for Chiasma, Inc.? Upgrade Your Profile and unlock all your annual reports.

Chiasma, Inc.

  • Ticker CHMA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Chiasma, Inc. Logo Image
  • 51-200 Employees
  • Based in Needham, Massachusetts
Chiasma is focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPEĀ®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. On June 26, 2020, ChiasmaMore received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog approved by the FDA. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.
Chiasma, Inc.

Most Recent Annual Report

Chiasma, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Chiasma, Inc. has reached its limit for free report views.

Older/Archived Annual Reports